{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:17:45Z","timestamp":1790788665185,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clbc.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T07:13:40Z","timestamp":1718781220000},"page":"e622-e632.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4353-3945","authenticated-orcid":false,"given":"Antoine","family":"El Kaddissi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Falcoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Chaigneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erion","family":"Dobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Goujon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meneveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Justine","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohair","family":"Selmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Viot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Molimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Monnien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Woronoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Curtit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Meynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clbc.2024.06.006_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"16","key":"10.1016\/j.clbc.2024.06.006_bib0002","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.clbc.2024.06.006_bib0003","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2024.06.006_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clbc.2024.06.006_bib0005","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1200\/JCO.1991.9.12.2148","article-title":"A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer","volume":"9","author":"Perez","year":"1991","journal-title":"J Clin Oncol"},{"issue":"4 Suppl 3","key":"10.1016\/j.clbc.2024.06.006_bib0006","first-page":"19","article-title":"Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand","volume":"11","author":"Bishop","year":"1997","journal-title":"Oncology (Williston Park)"},{"issue":"9769","key":"10.1016\/j.clbc.2024.06.006_bib0007","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet North Am Ed"},{"issue":"1362","key":"10.1016\/j.clbc.2024.06.006_bib0008","first-page":"30","article-title":"Eribulin mesylate (Halaven) for breast cancer","volume":"53","year":"2011","journal-title":"Med Lett Drugs Ther"},{"issue":"10","key":"10.1016\/j.clbc.2024.06.006_bib0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12032-019-1314-9","article-title":"Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer","volume":"36","author":"Ito","year":"2019","journal-title":"Med Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clbc.2024.06.006_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000489065","article-title":"Predictive factors of eribulin activity in metastatic breast cancer patients","volume":"94","author":"De Sanctis","year":"2018","journal-title":"Oncology"},{"issue":"47","key":"10.1016\/j.clbc.2024.06.006_bib0011","doi-asserted-by":"crossref","first-page":"e27859","DOI":"10.1097\/MD.0000000000027859","article-title":"Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.clbc.2024.06.006_bib0012","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/s12885-017-3598-5","article-title":"Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer","volume":"17","author":"Kashiwagi","year":"2017","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2024.06.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170634","article-title":"Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer","volume":"12","author":"Kashiwagi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2024.06.006_bib0014","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-018-1443-5","article-title":"Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment","volume":"16","author":"Kashiwagi","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.clbc.2024.06.006_bib0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12885-016-2436-5","article-title":"Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study","volume":"16","author":"Kobayashi","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2024.06.006_bib0016","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212506","article-title":"Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies","volume":"6","author":"Rossi","year":"2017","journal-title":"Drugs Context"},{"issue":"10028","key":"10.1016\/j.clbc.2024.06.006_bib0017","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clbc.2024.06.006_bib0018","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/dc.21794","article-title":"Update on liposarcoma: a review for cytopathologists","volume":"40","author":"Dodd","year":"2012","journal-title":"Diagn Cytopathol"},{"issue":"12","key":"10.1016\/j.clbc.2024.06.006_bib0019","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/sj.bjc.6690628","article-title":"Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis","volume":"80","author":"Pharoah","year":"1999","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.clbc.2024.06.006_bib0020","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1158\/0008-5472.CAN-15-0563","article-title":"p53: Protection against tumor growth beyond effects on cell cycle and apoptosis","volume":"75","author":"Wang","year":"2015","journal-title":"Cancer Res"},{"issue":"69","key":"10.1016\/j.clbc.2024.06.006_bib0021","doi-asserted-by":"crossref","first-page":"33232","DOI":"10.18632\/oncotarget.26075","article-title":"Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic","volume":"9","author":"Dembla","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.clbc.2024.06.006_bib0022","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00428-018-2301-9","article-title":"The new TNM-based staging of breast cancer","volume":"472","author":"Cserni","year":"2018","journal-title":"Virchows Arch"},{"issue":"12","key":"10.1016\/j.clbc.2024.06.006_bib0023","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1002\/ijc.32402","article-title":"Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program","volume":"145","author":"Jacot","year":"2019","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.clbc.2024.06.006_bib0024","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.clbc.2014.09.001","article-title":"Effects of second and subsequent lines of chemotherapy for metastatic breast cancer","volume":"15","author":"Park","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2024.06.006_bib0025","unstructured":"Expression of MDM2 in breast cancer - The Human Protein Atlas."},{"issue":"5","key":"10.1016\/j.clbc.2024.06.006_bib0026","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/j.clbc.2018.07.023","article-title":"Genetic markers in triple-negative breast cancer","volume":"18","author":"Sporikova","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2024.06.006_bib0027","unstructured":"A Phase 3, randomized, multi-center, open-label study of trastuzumab deruxtecan (T-DXd) versus investigator's choice chemotherapy in HER2-low, hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting (DESTINY-Breast06). clinicaltrials.gov; 2023."},{"issue":"3","key":"10.1016\/j.clbc.2024.06.006_bib0028","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clbc.2024.06.006_bib0029","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.06.006_bib0030","unstructured":"Curigliano G, Castelo-Branco L, Gennari A, Harbeck N, Criscitiello C, Trapani D. ESMO metastatic breast cancer living guidelines, 2023."}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092400171X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682092400171X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:50:15Z","timestamp":1726473015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682092400171X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S152682092400171X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.06.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}